Molecure SA
WSE:MOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Swedbank AB
STO:SWED A
|
SE |
|
Mobvista Inc
HKEX:1860
|
CN |
Molecure SA
EPS (Diluted)
Molecure SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Molecure SA
WSE:MOC
|
EPS (Diluted)
zł0
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Celon Pharma SA
WSE:CLN
|
EPS (Diluted)
-zł2
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabis Poland SA
WSE:CBD
|
EPS (Diluted)
zł0
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
See Also
What is Molecure SA's EPS (Diluted)?
EPS (Diluted)
-0.8
PLN
Based on the financial report for Dec 31, 2025, Molecure SA's EPS (Diluted) amounts to -0.8 PLN.
What is Molecure SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
11%
Over the last year, the EPS (Diluted) growth was 51%. The average annual EPS (Diluted) growth rates for Molecure SA have been 11% over the past three years .
